Subscribe
Today
Financial
Technology
Cyclical
Defensive
Healthcare
Energy
Industrials
Real Estate
Materials
Viewpoints
All Access Articles |
ABUS
Arbutus Biopharma Achieves 50% Functional Cure in Hepatitis B Trial
| 2024-11-15 |
PHARMACEUTICAL
Arbutus Biopharma Q3 2024 Financial Results – $130.8M Cash, $1.3M Revenue, $63-67M Cash Burn Est.
| 2024-11-06 |
PHARMACEUTICAL
